Clinical Trial Update: Safety Study on AdCD40L Gene Therapy for Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety study of AdCD40L gene therapy for bladder cancer has completed. The trial was sponsored by Uppsala University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• AdCD40L (adenovirus-delivered CD40 ligand gene therapy)

Snippet

Sponsor: Uppsala University | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: COMPLETED